Correction to: Etripamil Nasal Spray: Therapeutic Potential for Treating Paroxysmal Supraventricular Tachycardia

• Published in: American journal of cardiovascular drugs : drugs, devices, and other interventions Vol. 23; no. 6; pp. 735 - 736
• Main Authors: Huston, Jessica, Genovese, Ariana, Ashchi, Andrea, DeLuca, Amanda, Wiener, Jordyn, Deeb, Elias, Deeb, Alexander, Goldfaden, Rebecca F.
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.11.2023; Springer Nature B.V
• Subjects: Adenosine; Cardiac arrhythmia; Cardiology; Cardiomyopathy; Cardiovascular disease; Correction; Drug dosages; Heart; Medicine; Medicine & Public Health; Metabolism; Oral administration; Patients; Pharmacology/Toxicology; Pharmacotherapy; Quality of life; United States > US
• ISSN: 1175-3277; 1179-187X
• DOI: 10.1007/s40256-023-00595-4

The RAPID study population consists of 34 patients enrolled during Part 1 of NODE-301 who did not have a PSVT episode by the cut-off date and 658 newly enrolled patients who passed a test dose regimen of etripamil nasal spray 70 mg, randomized 1:1 to a dosing regimen of etripamil or placebo that allows patients to self-administer a second dose to treat a perceived PSVT episode [14]." Section 2.1, lines 26-31 currently reads as 'Tn the phase III study NODE-303, patient self-administration of etripamil 70 mg nasal spray during episodes of PSVT after the failure of vagal maneuver to terminate the arrhythmia resulted in first degree atrioventricular heart block in two subjects, with otherwise no difference in safety between etripamil and placebo [8]." Section 3, lines 11-13 currently reads as "The reduction of side effects and implications from these chronic medications may increase the quality of life for the patient [16]."